Yuka Kumagai
Senior Vice President, Head of Translational Research & Medicine Sumitomo Pharma America, Inc.
Seminars
Tuesday 27th January 2026
Enhanced Tumor Targeting & Therapeutic Window Expansion with SMP-3124: A Novel Liposome-Encapsulated CHK1 Inhibitor
1:15 pm
• See how Sumitomo Pharma America is enhancing tumor targeting with their novel liposomal CHK1 inhibitor, SMP-3124.
• Highlighting translational research insights that improve the likelihood of tumor response while mitigating toxicity limitations seen with earlier CHK1 programs
• Providing a trials-in-progress update on the ongoing Phase I study, sharing design, patient cohorts, and a general summary
